Shuyong Zhang

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 22

Top Topics

Epithelial Mesenchymal Transition

Top Venues

Cell death & disease

Cellular & molecular biology letters

Journal of experimental & clinical cancer research : CR

This page only lists publications with an associated author ORCID identifier.

Publications

Weisong Li, Kai Zhang, Wenjun Wang, Yuanyuan Liu, Jianming Huang, Meihong Zheng, Ling Li, Xinyu Zhang, Minjuan Xu, Guofang Chen, Liefeng Wang, Shuyong Zhang
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Hongfu Liu, Dongdong Zhou, Dongqin Liu, Xi Xu, Kai Zhang, Ruxia Hu, Peng Xiong, Changxin Wang, Xiangfu Zeng, Liefeng Wang, Shuyong Zhang
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer. Cell death & disease 15 (3) (2024)
Ming Tang, Shasha Yin, Hongliang Zeng, Ao Huang, Yujia Huang, Zhiyi Hu, Ab Rauf Shah, Shuyong Zhang, Haisen Li, Guofang Chen
The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway. Cell death & disease 15 (1) (2024)
Weisong Li, Chao Zheng, Xi Xu, Yujie Xia, Kai Zhang, Ao Huang, Xinyu Zhang, Yong Zheng, Guofang Chen, Shuyong Zhang
Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma. Cellular & molecular biology letters 29 (1) (2024)
Weisong Li, Chao Zheng, Xi Xu, Yujie Xia, Kai Zhang, Ao Huang, Xinyu Zhang, Yong Zheng, Guofang Chen, Shuyong Zhang
Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma. Cellular & molecular biology letters 29 (1) (2024)
Hongfu Liu, Dongdong Zhou, Dongqin Liu, Xi Xu, Kai Zhang, Ruxia Hu, Peng Xiong, Changxin Wang, Xiangfu Zeng, Liefeng Wang, Shuyong Zhang
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer. Cell death & disease 15 (3) (2024)
Ming Tang, Shasha Yin, Hongliang Zeng, Ao Huang, Yujia Huang, Zhiyi Hu, Ab Rauf Shah, Shuyong Zhang, Haisen Li, Guofang Chen
The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway. Cell death & disease 15 (1) (2024)
Weisong Li, Kai Zhang, Wenjun Wang, Yuanyuan Liu, Jianming Huang, Meihong Zheng, Ling Li, Xinyu Zhang, Minjuan Xu, Guofang Chen, Liefeng Wang, Shuyong Zhang
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Hongfu Liu, Dongdong Zhou, Dongqin Liu, Xi Xu, Kai Zhang, Ruxia Hu, Peng Xiong, Changxin Wang, Xiangfu Zeng, Liefeng Wang, Shuyong Zhang
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer. Cell death & disease 15 (3) (2024)
Weisong Li, Kai Zhang, Wenjun Wang, Yuanyuan Liu, Jianming Huang, Meihong Zheng, Ling Li, Xinyu Zhang, Minjuan Xu, Guofang Chen, Liefeng Wang, Shuyong Zhang
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Weisong Li, Chao Zheng, Xi Xu, Yujie Xia, Kai Zhang, Ao Huang, Xinyu Zhang, Yong Zheng, Guofang Chen, Shuyong Zhang
Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma. Cellular & molecular biology letters 29 (1) (2024)
Hongfu Liu, Dongdong Zhou, Dongqin Liu, Xi Xu, Kai Zhang, Ruxia Hu, Peng Xiong, Changxin Wang, Xiangfu Zeng, Liefeng Wang, Shuyong Zhang
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer. Cell death & disease 15 (3) (2024)
Ming Tang, Shasha Yin, Hongliang Zeng, Ao Huang, Yujia Huang, Zhiyi Hu, Ab Rauf Shah, Shuyong Zhang, Haisen Li, Guofang Chen
The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway. Cell death & disease 15 (1) (2024)
Hongfu Liu, Dongdong Zhou, Dongqin Liu, Xi Xu, Kai Zhang, Ruxia Hu, Peng Xiong, Changxin Wang, Xiangfu Zeng, Liefeng Wang, Shuyong Zhang
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer. Cell death & disease 15 (3) (2024)
Ming Tang, Shasha Yin, Hongliang Zeng, Ao Huang, Yujia Huang, Zhiyi Hu, Ab Rauf Shah, Shuyong Zhang, Haisen Li, Guofang Chen
The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway. Cell death & disease 15 (1) (2024)
Weisong Li, Chao Zheng, Xi Xu, Yujie Xia, Kai Zhang, Ao Huang, Xinyu Zhang, Yong Zheng, Guofang Chen, Shuyong Zhang
Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma. Cellular & molecular biology letters 29 (1) (2024)
Ming Tang, Shasha Yin, Hongliang Zeng, Ao Huang, Yujia Huang, Zhiyi Hu, Ab Rauf Shah, Shuyong Zhang, Haisen Li, Guofang Chen
The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway. Cell death & disease 15 (1) (2024)
Chao Zheng, Dongdong Zhou, Weisong Li, Yanhui Duan, Minwen Xu, Jie Liu, Jingpei Cheng, Youban Xiao, Han Xiao, Tao Gan, Jianmin Liang, Dexian Zheng, Liefeng Wang, Shuyong Zhang
Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer. Cell death & disease 14 (4) (2023)
Chao Zheng, Dongdong Zhou, Weisong Li, Yanhui Duan, Minwen Xu, Jie Liu, Jingpei Cheng, Youban Xiao, Han Xiao, Tao Gan, Jianmin Liang, Dexian Zheng, Liefeng Wang, Shuyong Zhang
Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer. Cell death & disease 14 (4) (2023)
Chao Zheng, Dongdong Zhou, Weisong Li, Yanhui Duan, Minwen Xu, Jie Liu, Jingpei Cheng, Youban Xiao, Han Xiao, Tao Gan, Jianmin Liang, Dexian Zheng, Liefeng Wang, Shuyong Zhang
Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer. Cell death & disease 14 (4) (2023)
Chao Zheng, Dongdong Zhou, Weisong Li, Yanhui Duan, Minwen Xu, Jie Liu, Jingpei Cheng, Youban Xiao, Han Xiao, Tao Gan, Jianmin Liang, Dexian Zheng, Liefeng Wang, Shuyong Zhang
Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer. Cell death & disease 14 (4) (2023)
Chao Zheng, Dongdong Zhou, Weisong Li, Yanhui Duan, Minwen Xu, Jie Liu, Jingpei Cheng, Youban Xiao, Han Xiao, Tao Gan, Jianmin Liang, Dexian Zheng, Liefeng Wang, Shuyong Zhang
Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer. Cell death & disease 14 (4) (2023)